MINI REVIEW article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1660401
Intravitreal Drug Injection for Glaucoma: Mechanisms, Clinical Efficacy, and Future Horizons
Provisionally accepted
- Eye Center, Xiamen University, Xiamen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Intravitreal drug injection has emerged as a transformative approach in glaucoma management, overcoming the limitations of traditional treatments such as poor compliance with topical medications and high complication rates of filtration surgery. This review synthesizes the mechanisms, clinical efficacy, and future directions of intravitreal drug injection in glaucoma management, with a focus on Anti-vascular endothelial growth factor (anti-VEGF) agents, sustained-release preparations, and intraoperative adjuvant injections. Anti-VEGF drugs, as the cornerstone for neovascular glaucoma (NVG), effectively regress iris neovascularization and reduce intraocular pressure (IOP), with aflibercept achieving an 86.7% regression rate and a 12.3 mmHg IOP reduction in clinical trials. Sustained-release preparations, leveraging porous structures or biodegradable carriers with differential pore sizes or degradation rates, enable long-term drug release (up to 6 months) and stable IOP control, addressing the need for frequent injections. Intraoperative adjuvant injections, such as epinephrine during minimally invasive glaucoma surgery (MIGS), further enhance surgical success by reducing scarring and improving IOP control. Despite these advancements, challenges remain, including reliance on primary disease control for anti-VEGF efficacy, carrier displacement risks, and the lack of real-time drug concentration monitoring. Emerging technologies, such as intelligent responsive delivery systems, nanorobotics, and Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9 (CRISPR-Cas9) gene editing, offer promising solutions to achieve precise, individualized therapy. This review highlights the shift from passive IOP reduction to active neurovascular regulation, emphasizing the potential of intravitreal injection to redefine glaucoma treatment paradigms.
Keywords: Intravitreal injection, Glaucoma, anti-vegf, Sustained-release technology, minimally invasive surgery
Received: 06 Jul 2025; Accepted: 06 Aug 2025.
Copyright: © 2025 Lin, Shi and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bin Lin, Eye Center, Xiamen University, Xiamen, China
Dongkan Li, Eye Center, Xiamen University, Xiamen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.